If a patient has a mutation that impairs the production of thromboxane A2 in platelets, which consequence is most likely?

💡 Explanation

Reduced thromboxane A2 impairs the platelet activation and aggregation needed for clot formation because thromboxane A2 amplifies the initial platelet response during hemostasis. Therefore, reduced production leads to impaired clotting, rather than enhanced clotting or effects on other blood cell types or clot breakdown.

• Which outcome occurs when antithrombin III's activity is significantly reduced in blood plasma?
• An individual with advanced cirrhosis experiences reduced urea production. Which outcome primarily explains why hepatic encephalopathy risk rises as cirrhosis worsens?
• If a patient exhibits elevated TSH levels following a partial thyroidectomy, which compensatory mechanism within the hypothalamic-pituitary-thyroid axis most likely maintains thyroid hormone levels?
• Why does bariatric surgery often cause type 2 diabetics to rapidly reduce or eliminate their need for insulin injections?
• A patient with peripheral neuropathy experiences diminished touch sensitivity in their feet. Why does wearing textured insoles *not* fully restore their balance, even though mechanoreceptors are stimulated?
• What causes concentrated urine production in the kidneys of a desert-dwelling mammal, given limited water intake?